Risk of Arrhythmic Death in Patients With Nonischemic Cardiomyopathy: JACC Review Topic of the Week.
cardiac magnetic resonance imaging
computational modeling
nonischemic cardiomyopathy
sudden cardiac death
ventricular arrhythmias
Journal
Journal of the American College of Cardiology
ISSN: 1558-3597
Titre abrégé: J Am Coll Cardiol
Pays: United States
ID NLM: 8301365
Informations de publication
Date de publication:
22 08 2023
22 08 2023
Historique:
received:
05
12
2022
revised:
21
04
2023
accepted:
30
05
2023
medline:
18
8
2023
pubmed:
17
8
2023
entrez:
17
8
2023
Statut:
ppublish
Résumé
Nonischemic cardiomyopathy (NICM) is common and patients are at significant risk for early mortality secondary to ventricular arrhythmias. Current guidelines recommend implantable cardioverter-defibrillator (ICD) therapy to decrease sudden cardiac death (SCD) in patients with heart failure and reduced left ventricular ejection fraction. However, in randomized clinical trials comprised solely of patients with NICM, primary prevention ICDs did not confer significant mortality benefit. Moreover, left ventricular ejection fraction has limited sensitivity and specificity for predicting SCD. Therefore, precise risk stratification algorithms are needed to define those at the highest risk of SCD. This review examines mechanisms of sudden arrhythmic death in patients with NICM, discusses the role of ICD therapy and treatment of heart failure for prevention of SCD in patients with NICM, examines the role of cardiac magnetic resonance imaging and computational modeling for SCD risk stratification, and proposes new strategies to guide future clinical trials on SCD risk assessment in patients with NICM.
Identifiants
pubmed: 37587585
pii: S0735-1097(23)06019-9
doi: 10.1016/j.jacc.2023.05.064
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
735-747Informations de copyright
Copyright © 2023 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Funding Support and Author Disclosures Dr Chrispin has received consulting fees from Biosense Webster; and has received honorarium from Abbott. Dr Navara has equity ownership in SafeBeat Rx. Dr Torbe has ownership of Boston Scientific stocks. Dr Cheung has received consulting fees from Abbott, Biotronik, and Boston Scientific; has received research grant support from Boston Scientific; and has received fellowship grant support from Abbott, Biosense, Biotronik, Boston Scientific, and Medtronic. Dr Lakdawala has received research support from Pfizer Inc; and has received consulting fees from Pfizer Inc, Bristol Myers Squibb, Cytokinetics, and Tenaya Inc. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.